Is PAVmed Series Stock a Good Investment?
PAVmed Series Investment Advice | PAVMZ |
- Examine PAVmed Series' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research PAVmed Series' leadership team and their track record. Good management can help PAVmed Series navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact PAVmed Series' business and its evolving consumer preferences.
- Compare PAVmed Series' performance and market position to its competitors. Analyze how PAVmed Series is positioned in terms of product offerings, innovation, and market share.
- Check if PAVmed Series pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about PAVmed Series' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in PAVmed Series Z stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if PAVmed Series Z is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine PAVmed Series Stock
Researching PAVmed Series' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years.
To determine if PAVmed Series is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding PAVmed Series' research are outlined below:
| PAVmed Series Z is way too risky over 90 days horizon | |
| PAVmed Series Z has some characteristics of a very speculative penny stock | |
| PAVmed Series Z appears to be risky and price may revert if volatility continues | |
| PAVmed Series Z has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 2.45 M. Net Loss for the year was (64.17 M) with loss before overhead, payroll, taxes, and interest of (2.37 M). | |
| PAVmed Series generates negative cash flow from operations | |
| PAVmed Series Z has a frail financial position based on the latest SEC disclosures |
PAVmed Series' profitablity analysis
The company has Profit Margin (PM) of 6.03 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of (11.62) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $11.62.Determining PAVmed Series' profitability involves analyzing its financial statements and using various financial metrics to determine if PAVmed Series is a good buy. For example, gross profit margin measures PAVmed Series' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of PAVmed Series' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in PAVmed Series' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of PAVmed Series Z. Check PAVmed Series' Beneish M Score to see the likelihood of PAVmed Series' management manipulating its earnings.
Basic technical analysis of PAVmed Stock
As of the 22nd of March, PAVmed Series holds the Mean Deviation of 19.33, market risk adjusted performance of 1.34, and Coefficient Of Variation of 736.86. Concerning fundamental indicators, the technical analysis model allows you to check practical technical drivers of PAVmed Series, as well as the relationship between them.PAVmed Series' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific PAVmed Series insiders, such as employees or executives, is commonly permitted as long as it does not rely on PAVmed Series' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases PAVmed Series insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Baxter Timothy E a day ago Acquisition by Baxter Timothy E of 450000 shares of PAVmed Series at 0.48 subject to Rule 16b-3 | ||
Glennon Michael J over three months ago Acquisition by Glennon Michael J of 450000 shares of PAVmed Series at 0.48 subject to Rule 16b-3 |
Understand PAVmed Series' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing PAVmed Series' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1301 | |||
| Market Risk Adjusted Performance | 1.34 | |||
| Mean Deviation | 19.33 | |||
| Semi Deviation | 18.38 | |||
| Downside Deviation | 25.48 | |||
| Coefficient Of Variation | 736.86 | |||
| Standard Deviation | 31.98 | |||
| Variance | 1023.01 | |||
| Information Ratio | 0.1375 | |||
| Jensen Alpha | 4.55 | |||
| Total Risk Alpha | 6.76 | |||
| Sortino Ratio | 0.1726 | |||
| Treynor Ratio | 1.33 | |||
| Maximum Drawdown | 180.0 | |||
| Value At Risk | (32.00) | |||
| Potential Upside | 67.01 | |||
| Downside Variance | 649.2 | |||
| Semi Variance | 337.97 | |||
| Expected Short fall | (26.13) | |||
| Skewness | 1.93 | |||
| Kurtosis | 7.58 |
| Risk Adjusted Performance | 0.1301 | |||
| Market Risk Adjusted Performance | 1.34 | |||
| Mean Deviation | 19.33 | |||
| Semi Deviation | 18.38 | |||
| Downside Deviation | 25.48 | |||
| Coefficient Of Variation | 736.86 | |||
| Standard Deviation | 31.98 | |||
| Variance | 1023.01 | |||
| Information Ratio | 0.1375 | |||
| Jensen Alpha | 4.55 | |||
| Total Risk Alpha | 6.76 | |||
| Sortino Ratio | 0.1726 | |||
| Treynor Ratio | 1.33 | |||
| Maximum Drawdown | 180.0 | |||
| Value At Risk | (32.00) | |||
| Potential Upside | 67.01 | |||
| Downside Variance | 649.2 | |||
| Semi Variance | 337.97 | |||
| Expected Short fall | (26.13) | |||
| Skewness | 1.93 | |||
| Kurtosis | 7.58 |
Consider PAVmed Series' intraday indicators
PAVmed Series intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of PAVmed Series stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.34 | |||
| Daily Balance Of Power | 1.294118 | |||
| Rate Of Daily Change | 1.8 | |||
| Day Median Price | 0.0082 | |||
| Day Typical Price | 0.0088 | |||
| Market Facilitation Index | 0.0034 | |||
| Price Action Indicator | 0.0039 | |||
| Period Momentum Indicator | 0.0044 | |||
| Relative Strength Index | 44.47 |
PAVmed Stock media impact
Far too much social signal, news, headlines, and media speculation about PAVmed Series that are available to investors today. That information is available publicly through PAVmed media outlets and privately through word of mouth or via PAVmed internal channels. However, regardless of the origin, that massive amount of PAVmed data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of PAVmed Series news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of PAVmed Series relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to PAVmed Series' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive PAVmed Series alpha.
PAVmed Series Corporate Management
| Michael Gordon | General VP | Profile | |
| Deepika Lakhani | Chief VP | Profile | |
| Brian MD | Chief VP | Profile | |
| Michael Parks | Vice Relations | Profile | |
| Victoria Lee | Senior Officer | Profile |
Additional Tools for PAVmed Stock Analysis
When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.